| Literature DB >> 29346770 |
Atsushi Takata1, Noriko Miyake1, Yoshinori Tsurusaki2, Ryoko Fukai3, Satoko Miyatake4, Eriko Koshimizu1, Itaru Kushima5, Takashi Okada5, Mako Morikawa5, Yota Uno5, Kanako Ishizuka5, Kazuhiko Nakamura6, Masatsugu Tsujii7, Takeo Yoshikawa8, Tomoko Toyota8, Nobuhiko Okamoto9, Yoko Hiraki10, Ryota Hashimoto11, Yuka Yasuda12, Shinji Saitoh13, Kei Ohashi13, Yasunari Sakai14, Shouichi Ohga14, Toshiro Hara15, Mitsuhiro Kato16, Kazuyuki Nakamura17, Aiko Ito18, Chizuru Seiwa18, Emi Shirahata18, Hitoshi Osaka19, Ayumi Matsumoto19, Saoko Takeshita20, Jun Tohyama21, Tomoko Saikusa22, Toyojiro Matsuishi22, Takumi Nakamura23, Takashi Tsuboi24, Tadafumi Kato25, Toshifumi Suzuki26, Hirotomo Saitsu1, Mitsuko Nakashima1, Takeshi Mizuguchi1, Fumiaki Tanaka27, Norio Mori28, Norio Ozaki5, Naomichi Matsumoto29.
Abstract
Recent studies have established important roles of de novo mutations (DNMs) in autism spectrum disorders (ASDs). Here, we analyze DNMs in 262 ASD probands of Japanese origin and confirm the "de novo paradigm" of ASDs across ethnicities. Based on this consistency, we combine the lists of damaging DNMs in our and published ASD cohorts (total number of trios, 4,244) and perform integrative bioinformatics analyses. Besides replicating the findings of previous studies, our analyses highlight ATP-binding genes and fetal cerebellar/striatal circuits. Analysis of individual genes identified 61 genes enriched for damaging DNMs, including ten genes for which our dataset now contributes to statistical significance. Screening of compounds altering the expression of genes hit by damaging DNMs reveals a global downregulating effect of valproic acid, a known risk factor for ASDs, whereas cardiac glycosides upregulate these genes. Collectively, our integrative approach provides deeper biological and potential medical insights into ASDs.Entities:
Keywords: AGO1; ASD; ATP1A3; ATP2B2; GGNBP2; MCM6; cardiac glycosides; cerebellum; de novo mutations; striatum
Mesh:
Year: 2018 PMID: 29346770 DOI: 10.1016/j.celrep.2017.12.074
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423